Retrospective analysis of acute kidney injury incidence in anti-infection therapy using vancomycin com-bined with imipenem/cilastatin sodium or meropenem
OBJECTIVE To evaluate the difference in the incidence of acute kidney injury(AKI)in anti-infection treatment with vancomycin combined with imipenem/cilastatin sodium or meropenem,providing reference for clinical decision-making.METHODS A retrospective analysis method was adopted,selecting patients hospitalized in Xiaogan Central Hospital from Janu-ary 2020 to December 2022 who had used imipenem/cilastatin sodium combined with vancomycin or meropenem combined with vancomycin.The minimum duration of combination drug treatment was 72 hours.The primary research endpoint was the inci-dence of AKI,and the secondary endpoint was risk factors for AKI.RESULTS A total of 208 patients were included in the analysis,with 82 cases in the imipenem/cilastatin sodium and vancomycin group,and 126 cases in the Meropenem and Vancomy-cin group.The incidence of AKI in the imipenem/cilastatin sodium group was 8.54％,and in the meropenem group was 20.63％,the incidence of AKI between the two groups was statistically significant(P=0.032).The secondary endpoint showed that diabetes was a risk factor for AKI.CONCLUSION Compared with the use of meropenem combined with vancomycin,the incidence of AKI during anti-infection treatment with imipenem/cilastatin sodium combined with vancomycin is lower.
NETL
NSTL
万方数据
